Journal Information
Vol. 59. Issue 6.
Pages 393 (June 2023)
Share
Share
Download PDF
More article options
Vol. 59. Issue 6.
Pages 393 (June 2023)
Clinical Image
Full text access
Bullous Lung Disease Post-COVID
Visits
2154
Carlos Manzano Senraa,
Corresponding author
carlosmanzanosenra555@gmail.com

Corresponding author.
, Ricard Pifarré Teixidóa, Marina Asunción Pardina Solanob
a Servicio de Neumología, Hospital Universitario Arnau de Vilanova, Lleida, Spain
b Servicio de Radiodiagnóstico, Hospital Universitario Arnau de Vilanova, Lleida, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

A 40 year old patient, non smoker with no history of pathology, required hospital admission for bilateral SARS-CoV2 pneumonia and basal oxygen saturation of 93%. Received treatment with oxygen therapy, dexamethasone and a single dose of tocilizumab with correct clinical evolution.

After discharge, self-limited haemoptoic expectoration was presented. A thoracic computed tomography scan showed multiple bilateral cavitated pulmonary lesions, and was readmitted to hospital. Physical examination and primary blood analysis were normal. A bronchoscopy was performed showing hematic secretions in the left lower lobe. All microbiological samples were negative.

In absence of clinical manifestations and given the normality of the studies, the case was classified as post-COVID bullous disease, and an ambulatory thoracic CT scan was performed after 3 months, showing radiological resolution of lesions (Fig. 1) and normal respiratory function test.

Fig. 1.

Thoracic CT images observing bilateral bullous injuries and their comparison at the same level in a CT control showing their resolution after 3 months.

(0.59MB).

Bullous lung disease post-COVID is a rare disease that consists on the apparition of air bullae of 1cm or larger inside of the lung parenchyma on immediate post-COVID. It has been reported some cases of gigant bulla that required surgical treatment post-COVID1 and cases of bullous lung disease in context of severe pneumonitis2 with favorable evolution without medical intervention, as it occurred in our case.

Funding

The authors declare that no funding was received for this article.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References
[1]
J.A. Rodríguez Blanco, J.D. Rodríguez Blanco, J.J. Rodríguez Blanco, M.C. Martínez Ávila, M.C. Acuña Caballero, C.E. Remolina.
Enfermedad bullosa como complicación pulmonar en la convalecencia de COVID-19.
Rev Colomb Neumol, 32 (2021), pp. 66-71
[2]
S. Berhane, A. Tabor, A. Sahu, A. Singh.
Development of bullous lung disease in a patient with severe COVID-19 pneumonitis.
BMJ Case Rep, 13 (2020),
Copyright © 2023. SEPAR
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?